Lineage Pays $4.3 Million for a Huntington's Program and Calls It Transformational
A $250 million cell-therapy developer pivots its story away from an OpRegen it can't discuss and toward a striatal transplant it has owned for eight hours — with the stock down 29% in 90 days and no tape confirmation yet
LCTX · Earnings Call · 2026-11-12
Eight Hours of Ownership
Brian Culley opened Lineage's third-quarter call the way he opens every call: with OpRegen, the Roche/Genentech-partnered retinal cell program that has been the company's entire investment case for years. Four paragraphs later, the call changed shape. “Just a few minutes ago, we announced that we had acquired NeuroAirmid Therapeutics, a private biotech company founded on technology licensed from the lab of world-leading Huntington's disease researcher, Dr. Leslie Thompson.” — Brian Culley, Chief Executive Officer · 2026-11-12 The asset is HUNT1, an allogeneic neural progenitor cell therapy injected directly into the striatum of Huntington's disease patients, currently in a Phase Ib/IIa called REGEN4HD run out of UC Irvine. The framing was conspicuous. Culley laid out a "10 key points" list, walked the audience through the science, the economics, the manufacturing fit and the competitive landscape — and then, when Mayank Mamtani asked what a good 12-month readout would look like, reminded everyone how fresh this all is: “It's correct that it's early. We've owned it for 8 hours.” — Brian Culley, Chief Executive Officer · 2026-11-12 That is a fair summary of the risk. Six patients have been dosed across Cohorts A and B, no serious adverse events reported, and the primary endpoint is safety at six weeks. Everything else — the UHDRS functional scores, the neurofilament light chain, the FDG-PET — is exploratory. What is far less ambiguous is that Lineage's narrative vocabulary has rotated. The company's own keyword registry has been dominated for a year by AlloSCOPE, RPE transplant language, the DOSED study and islet cell work. This quarter the biggest movers are all Huntington-adjacent: HUNT1, Huntington, NeuroAirmid, striatum, neurons, precursor, HUNT1 program. That is a genuinely new theme for this company — not a rephrasing of an old one — and it arrived with a companion admission: the pipeline is now three clinical-stage assets, and the newest one is the only one management can speak freely about.The Price of a Third Clinical Asset
Jill Howe's numbers are the part of the deck that actually holds up to scrutiny.That is $2.4 million cash plus roughly 2.2 million shares, with another tranche due on the first anniversary and all remaining consideration contingent on clinical progress and payable half in stock at Lineage's election. Ongoing clinical cost is under $2 million a year, and the trial itself is majority-funded by a $12 million CIRM grant to UC Irvine that Lineage co-funds up to $3.1 million. Against a stated budget run rate of roughly $30 million a year, this is a rounding error. The deal is small. The word management used for it was "transformational." Both can be true, but only one of them is arithmetic. The balance sheet got the real headline: “As of September 30, 2026, we had $45.2 million in cash, cash equivalents and marketable securities, which we expect will fund planned operations into the second quarter of 2028.” — Jill Howe, Chief Financial Officer · 2026-11-12 That is one quarter earlier than prior guidance — the first time in memory this company has shortened its runway rather than extended it. The last filed balance sheet, for the quarter ended August 3, showed effective net cash of about $27 million, down 10% year over year, so the $45.2 million figure reflects subsequent warrant exercises, not operating cash generation. Operating cash generation is the problem. Total revenue of about $1 million fell 61% year over year from a 2026Q1 peak of $4 million, as deferred Roche collaboration revenue burns off and the Demant research collaboration slows. Research and development ran at roughly five times revenue in the latest quarter. And the reported net income of $4.2 million is an artifact, not a profit — it comes from fair-value remeasurement of the warrant liability in a falling share price. Lineage's income statement now improves when its stock goes down. Which brings up the biggest lever nobody on the call wanted to dwell on: a price-to-revenue multiple above 25x sitting on top of $32 million of warrants struck at $0.91, a three-year term that condenses to 90 days if Roche and Genentech merely disclose intent to run a controlled OpRegen trial. The single largest cash event in Lineage's control belongs to a partner and is triggered by a press release.In the aggregate, our external cash payments on day 1 were approximately $4.3 million, a number we feel not only reflects exceptional value for clinical stage assets, but also fits well within our capability for investment.